Development of Fab′ fragments of anti-GD2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma
- 27 March 2003
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 197 (1-2) , 199-204
- https://doi.org/10.1016/s0304-3835(03)00099-5
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Targeted delivery of antisense oligonucleotides in cancerJournal of Controlled Release, 2001
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor EffectsJNCI Journal of the National Cancer Institute, 2000
- Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasisNature Medicine, 2000
- GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinideInternational Journal of Cancer, 1999
- Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.Journal of Clinical Oncology, 1998
- A metastatic neuroblastoma model in SCID miceInternational Journal of Cancer, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Development of anti-p185HER2 immunoliposomes for cancer therapy.Proceedings of the National Academy of Sciences, 1995
- Prognostic Value of Immunocytologic Detection of Bone Marrow Metastases in NeuroblastomaNew England Journal of Medicine, 1991